Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:BLRX NASDAQ:BRNS NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$7.89$5.11$3.39▼$16.00$85.43M0.8137,180 shs242,138 shsBLRXBioLineRx$3.87-2.8%$4.54$2.30▼$35.02$16.50M1.1534,392 shs17,850 shsBRNSBarinthus Biotherapeutics$1.42-4.4%$1.13$0.64▼$2.92$56.47M-0.743.84 million shs43,281 shsMNOVMediciNova$1.43+7.9%$1.33$1.12▼$2.55$70.14M0.3545,950 shs68,485 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics0.00%+17.94%+57.49%+56.55%-30.67%BLRXBioLineRx0.00%-8.94%-16.41%+12.50%-87.68%BRNSBarinthus Biotherapeutics0.00%-20.95%+45.13%+55.15%-5.03%MNOVMediciNova0.00%-2.05%+13.49%-5.30%+6.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.0481 of 5 stars3.53.00.00.02.51.71.3BLRXBioLineRx2.0748 of 5 stars3.83.00.00.00.00.01.3BRNSBarinthus Biotherapeutics2.2593 of 5 stars3.53.00.00.00.60.81.3MNOVMediciNova2.6972 of 5 stars3.84.00.00.02.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00280.23% UpsideBLRXBioLineRx 3.50Strong Buy$26.00571.83% UpsideBRNSBarinthus Biotherapeutics 3.00Buy$6.25341.70% UpsideMNOVMediciNova 3.50Strong Buy$7.00389.51% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, AVTX, BRNS, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.006/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K194.20N/AN/A$12.80 per share0.62BLRXBioLineRx$28.94M0.57N/AN/A$4.04 per share0.96BRNSBarinthus Biotherapeutics$14.97M3.81N/AN/A$3.23 per share0.44MNOVMediciNova$1M70.14N/AN/A$1.07 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)BLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/21/2025 (Estimated)BRNSBarinthus Biotherapeutics-$61.07M-$1.64N/AN/AN/AN/A-46.43%-38.50%8/6/2025 (Estimated)MNOVMediciNova-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)Latest BLRX, AVTX, BRNS, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025BLRXBioLineRx-$0.35N/AN/AN/AN/AN/A8/14/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.33N/AN/AN/AN/AN/A8/14/2025N/AMNOVMediciNova-$0.07N/AN/AN/AN/AN/A8/11/2025Q2 2025AVTXAvalo Therapeutics-$1.43N/AN/AN/AN/AN/A5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 million5/13/2025Q1 2025MNOVMediciNova-$0.14-$0.06+$0.08-$0.06N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61BLRXBioLineRx0.372.272.04BRNSBarinthus BiotherapeuticsN/A9.189.18MNOVMediciNovaN/A17.6617.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%BLRXBioLineRx1.56%BRNSBarinthus Biotherapeutics25.20%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%BLRXBioLineRx1.10%BRNSBarinthus Biotherapeutics10.70%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.50 millionNot OptionableBLRXBioLineRx404.26 million4.22 millionOptionableBRNSBarinthus Biotherapeutics10740.34 million36.02 millionN/AMNOVMediciNova1049.05 million42.38 millionOptionableBLRX, AVTX, BRNS, and MNOV HeadlinesRecent News About These CompaniesMediciNova signs standby equity purchase agreement for up to $30MAugust 1 at 9:04 AM | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1 at 6:34 AM | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31 at 8:19 PM | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31 at 7:30 PM | globenewswire.comMediciNova's (MNOV) Buy Rating Reiterated at D. Boral CapitalJuly 25, 2025 | marketbeat.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | globenewswire.comMediciNova, Inc. (MNOV) stock price, news, quote & history – Yahoo ...July 12, 2025 | au.finance.yahoo.comMediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comMediciNova price target lowered to $5 from $6 at B. RileyJune 17, 2025 | finance.yahoo.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14, 2025 | globenewswire.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comMediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MNDDecember 5, 2024 | quiverquant.comQMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MNDDecember 5, 2024 | globenewswire.comMediciNova Inc.December 5, 2024 | wsj.comD. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy RecommendationDecember 3, 2024 | msn.comMediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finanznachrichten.deMediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersNovember 20, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLRX, AVTX, BRNS, and MNOV Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$7.89 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.90 +0.02 (+0.19%) As of 08/1/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.BioLineRx NASDAQ:BLRX$3.87 -0.11 (-2.76%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.92 +0.05 (+1.42%) As of 08/1/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Barinthus Biotherapeutics NASDAQ:BRNS$1.42 -0.07 (-4.39%) Closing price 08/1/2025 03:51 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 08/1/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.MediciNova NASDAQ:MNOV$1.43 +0.11 (+7.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.38 -0.05 (-3.85%) As of 08/1/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
